Year
2020
Status
Active
Team
Field
Immunology
Location
Oss (NL)
Fund
BGV IV
Citryll
Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases.
2020
Active
Immunology
Oss (NL)
BGV IV
Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases.